In March 2010, the European  Commission announced that the  FLUPHARM consortium  including twelve  partners  from  Germany,  Austria,  France,  Spain,  Slovakia,  and  Belgium would receive a 6 million EUR grant over a period of 3.5 years. The project started in November 2010 with the aim to develop novel inhibitors against the cap-snatching activity of the influenza viral polymerase, and to advance a lead candidate into clinical development. In addition, the partners will enhance the fundamental understanding of the structure and cellular function of the influenza polymerase.